Literature DB >> 33817284

Relationship between hemodynamic parameters and portal venous pressure in cirrhosis patients with portal hypertension.

Hongjuan Yao1, Yongliang Wang2.   

Abstract

Cirrhosis caused by viral and alcoholic hepatitis is an essential cause of portal hypertension (PHT). The incidence of PHT complication is directly proportional to portal venous pressure (PVP), and the clinical research of PVP and its hemodynamic indexes is of great significance for deciding the treatment strategy of PHT. Various techniques are currently being developed to decrease portal pressure but hemodynamic side effects may occur. In this article, the hemodynamic indexes of cirrhotic PHT patients were studied to explore the correlation between the index and PVP and to evaluate the clinical value of Doppler ultrasound in measuring PVP in patients with PHT. This was achieved by selecting 90 cirrhotic PHT patients who underwent transjugular intrahepatic portosystemic shunt in our hospital from June 2015 to September 2019. Fifty healthy people who had a physical examination in the hospital in the same period were selected as the control group. The liver hemodynamic parameters of two groups were measured by Doppler ultrasound, and the cirrhotic PHT patients were graded by the Child-Pugh grading method to evaluate the liver function and measure the PVP value. The results showed that both the central portal vein velocity (PVV) and splenic vein velocity (SVV) of the PHT group were lower than those of the control group. Also, the portal vein diameter (PVD), portal venous flow and splenic vein diameter (SVD) were higher than those of the control group (all Ps < 0.05). Among liver function graded PHT patients, the PVD, PVV, SVD and SVV were significantly different (all Ps < 0.05). Furthermore, the PVP of patients with liver function grades A, B and C was 38.9 ± 1.4, 40.6 ± 5.1 and 42.5 ± 4.8 cmH2O, respectively, with a significant difference. It can be concluded from this study that Doppler ultrasound can be used as a tool for clinical assessment of PHT in cirrhosis patients. Doppler ultrasound showed a good prospect in noninvasive detection of PHT in cirrhosis; however, this technique needs application on large sample population study to validate the results.
© 2020 Hongjuan Yao and Yongliang Wang, published by De Gruyter.

Entities:  

Keywords:  Doppler; hemodynamics; portal hypertension; portal venous pressure; statistical analysis

Year:  2020        PMID: 33817284      PMCID: PMC7874537          DOI: 10.1515/biol-2020-0101

Source DB:  PubMed          Journal:  Open Life Sci        ISSN: 2391-5412            Impact factor:   0.938


  28 in total

1.  Amelioration of cirrhotic portal hypertension by targeted cyclooxygenase-1 siRNA delivery to liver sinusoidal endothelium with polyethylenimine grafted hyaluronic acid.

Authors:  Liteng Lin; Mingyue Cai; Shaohui Deng; Wensou Huang; Jingjun Huang; Xinghua Huang; Mingsheng Huang; Yong Wang; Xintao Shuai; Kangshun Zhu
Journal:  Nanomedicine       Date:  2017-07-13       Impact factor: 5.307

2.  [Diagnostic value of transient elastography for diagnosis of idiopathic non-cirrhotic portal hypertension].

Authors:  C Y He; Y Lyu; H Chen; H B Liu; Q H Wang; J H Fan; B H Luo; T L Yu; X L Yuan; J Tie; J Niu; W G Guo; Z X Yin; G H Han
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2018-04-20

3.  Non-cirrhotic Portal Hypertension Associated with Didanosine and Streptococcus agalactiae Infection: A Case Report.

Authors:  Vesna Turkulov; Maja Ruzic; Dajana Lendak; Daniela Maric; Snezana Brkic; Ludovico Abenavoli
Journal:  Rev Recent Clin Trials       Date:  2016

Review 4.  Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement.

Authors:  Vincenzo La Mura; Antonio Nicolini; Giulia Tosetti; Massimo Primignani
Journal:  World J Hepatol       Date:  2015-04-08

5.  Transjugular intrahepatic portosystemic shunt placement before abdominal intervention in cirrhotic patients with portal hypertension: lessons from a pilot study.

Authors:  Nadim Fares; Marie-Angèle Robic; Jean-Marie Péron; Fabrice Muscari; Philippe Otal; Bertrand Suc; Jean-Pierre Vinel; Christophe Bureau
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 2.566

6.  Color Doppler velocity profile assessment of portal hemodynamics in cirrhotic patients with portal hypertension: correlation with esophageal variceal bleeding.

Authors:  X Y Yin; M D Lu; J F Huang; X Y Xie; L J Liang
Journal:  J Clin Ultrasound       Date:  2001-01       Impact factor: 0.910

Review 7.  Pathophysiology of portal hypertension and variceal bleeding.

Authors:  T C Mahl; R J Groszmann
Journal:  Surg Clin North Am       Date:  1990-04       Impact factor: 2.741

8.  Role of splanchnic hemodynamics in liver regeneration after living donor liver transplantation.

Authors:  Shui-Ming Jiang; Guang-Wen Zhou; Rui Zhang; Cheng-Hong Peng; Ji-Qi Yan; Liang Wan; Chuan Shen; Hao Chen; Qing-Yu Li; Bai-Yong Shen; Hong-Wei Li
Journal:  Liver Transpl       Date:  2009-09       Impact factor: 5.799

9.  Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease.

Authors:  Sophie Restellini; Nicolas Goossens; Sophie Clément; Nicolas Lanthier; Francesco Negro; Laura Rubbia-Brandt; Laurent Spahr
Journal:  World J Hepatol       Date:  2018-01-27

10.  The Evaluation of Serum Ascites Albumin Gradient and Portal Hypertensive changes in Cirrhotic Patients with Ascites.

Authors:  Forhad Hossain Md Shahed; Salimur Rahman
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-07-09
View more
  1 in total

1.  Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.

Authors:  Takanori Mukozu; Hidenari Nagai; Daigo Matsui; Kunihide Mohri; Go Watanabe; Naoyuki Yoshimine; Makoto Amanuma; Kojiro Kobayashi; Yu Ogino; Yasushi Matsukiyo; Teppei Matsui; Yasuko Daido; Noritaka Wakui; Mie Shinohara; Koichi Momiyama; Koji Higai; Yoshinori Igarashi
Journal:  Cancer Chemother Pharmacol       Date:  2021-10-10       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.